Drug
Gonadotropin-releasing Hormone Analog clinical trials
- studies test it
- 47
- open now
- 6
- in phase 3
- 15
- first study started
- 2000
Keep track of what changes. Save the Gonadotropin-releasing Hormone Analog studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
47 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 17
- Phase 3
- 15
- Phase 4
- 7
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 42
Memorial Sloan Kettering Cancer Center (2) · Genentech, Inc. (2) · Radiation Therapy Oncology Group (2) · Alliance for Clinical Trials in Oncology (2) · Cairo University (2) · Assiut University (2) · Shaare Zedek Medical Center (2) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Abiraterone (3) · Chorionic Gonadotropin (3) · Gonadotropin Releasing Hormone Antagonist (3) · Letrozole (3) · Abiraterone Acetate (2) · Apalutamide (2) · Palbociclib (2) · Bicalutamide (2)
Studies
Open first, then newest update. How each study uses Gonadotropin-releasing Hormone Analog is read from its arms, and is right about nine times in ten.
Testing it · 47
- Effect of GnRH Agonist in FETNot yet recruitingPhase 1/2Assiut UniversityNCT07653282Written as GnRH agonist
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular ClassificationRecruitingPhase 2/3Fudan UniversityNCT07319429Written as GnRH agonist and Letrozole
- FET in AdenomyosisNot yet recruitingNot applicableIndira IVF Hospital Pvt LtdNCT06913075Written as GnRH agonist and Letrozole
- Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or AdenomyosisRecruitingPhase 2/3Hopital FochNCT04356664Written as GnRH agonist
- Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo TransferNot yet recruitingPhase 4National Taiwan University HospitalNCT07269392Written as GnRH agonist
- Value of LNG-IUS as Fertility-preserving Treatment of EAH and ECRecruitingPhase 2/3West China Second University HospitalNCT03463252Written as GnRH agonist
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04262154Written as GnRH analog
- Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate CancerActive, not recruitingPhase 2Mayo ClinicNCT06369610Written as Gonadotropin-releasing Hormone Analog
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingPhase 2Janssen Pharmaceutical K.K.NCT04325828Written as GnRH Agonist
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03332797Written as LHRH Agonist
- Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During ChemotherapyCompletedNot applicableHelwan UniversityNCT07127315Written as Gonadotropin-releasing hormone agonist
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsActive, not recruitingPhase 2Rana McKay, MDNCT05498272Written as LHRH agonist
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03436654Written as GnRH agonist/antagonist
- INTREPId (INTermediate Risk Erection PreservatIon Trial)Active, not recruitingPhase 2Brigham and Women's HospitalNCT04025372Written as GnRH Agonist
- Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate CancerActive, not recruitingEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT03511196Written as Adaptive Androgen Deprivation Therapy (ADT)
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate CancerActive, not recruitingPhase 3Radiation Therapy Oncology GroupNCT00567580Written as LHRH agonist
- Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)CompletedPhase 3Ferring PharmaceuticalsNCT03809429Written as FE 999049 + GnRH agonist (GONAPEPTYL)
- Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in AdenomyosisActive, not recruitingPhase 4Centre for Endocrinology and Reproductive Medicine, ItalyNCT03421639Written as GnRH analog (11.25mg Leuprolide acetate)
- Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy RatesStatus unknownNot applicableShaare Zedek Medical CenterNCT05838105Written as GnRH agonist
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate CancerActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT00430183Written as LHRH agonist
See all 47 studies that test Gonadotropin-releasing Hormone Analog →
Given in every arm · 42 — Gonadotropin-releasing Hormone Analog is usual care beside what is tested
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as GnRH agonist/antagonist
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303Written as Gonadotropin-releasing Hormone Analog
- BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNot yet recruitingPhase 1/2University of Illinois at ChicagoNCT07596212Written as GnRH agonist
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentRecruitingNot applicableNanjing UniversityNCT07128394Written as Gonadotropin-Releasing Hormone Agonist (GnRH-a)
- Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone MetastasesRecruitingNot applicableZhujiang HospitalNCT05740488Written as Luteinizing Hormone-Releasing Hormone Analog
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingPhase 3Fudan UniversityNCT05891093Written as LHRH agonist
- Luteal Phase Ovarian Stimulation With Follitropin Delta and DydrogesteroneRecruitingNot applicableCRG UZ BrusselNCT05521828Written as GnRH agonist (Gonapeptyl)
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingPhase 2Shengjing HospitalNCT05638594Written as Gonadotropin-releasing hormone agonist
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996Written as LHRH Agonist
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Written as LHRH Agonist
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252Written as Luteinizing hormone-releasing hormone (LHRH) agonist
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934Written as Luteinizing hormone-releasing hormone (LHRH) agonist
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Written as LHRH Agonist
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingPhase 2Hoffmann-La RocheNCT04576455Written as LHRH Agonist
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04546009Written as LHRH Agonist
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT06001762Written as LHRH Agonist
- Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentTerminatedPhase 1Eli Lilly and CompanyNCT05999968Written as LHRH agonist/antagonist
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as LHRH Agonist
- Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT00329043Written as LHRH Agonist
- Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateActive, not recruitingPhase 3University of SydneyNCT04136353Written as Luteinizing Hormone-Releasing Hormone Analog
Showing 20 of 42.
As the comparator · 6 — what is tested is compared with Gonadotropin-releasing Hormone Analog
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP TrialRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07466498Written as Gonadotropin-releasing Hormone Analog
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingPhase 2Rutgers, The State University of New JerseyNCT02949284Written as Gonadotropin-releasing Hormone Analog
- Cardiovascular Events in GnRH Agonist vs. AntagonistStatus unknownPhase 2Rabin Medical CenterNCT04182594Written as GnRH agonist
- Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone AgonistsCompletedPhase 4Rabin Medical CenterNCT02475057Written as LHRH agonist
- Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerWithdrawnPhase 2University of ChicagoNCT03058939Written as LHRH agonist
- Degarelix Neo-Adjuvant Radical Prostatectomy TrialCompletedPhase 2University Health Network, TorontoNCT01674270Written as LHRH Agonist